ITUS Corporation

14 articles about ITUS Corporation

• ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX

  9/28/2018

  ITUS Corporation today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc.  

• Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

  9/5/2018

  ITUS Corporation and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018. The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer.

• ITUS Corporation to Present at Next Generation Dx Summit

  8/17/2018

  ITUS Corporation announced that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th.

• Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy

  8/1/2018

  ITUS Corporation (NASDAQ: ITUS) today announced that it and its research partner, Moffitt Cancer Center, have requested a meeting with the US FDA to review the plan for advancing their CAR-T therapy for Ovarian Cancer into human clinical trials.

• ITUS Corporation Releases Results for Cchek™ Breast Cancer Study

  7/30/2018

  Cchek™ is a non-invasive (utilizing a blood sample), artificial intelligence (AI) guided, liquid biopsy cancer detection platform

• ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer

  7/6/2018

  Cchek™ technology has demonstrated the ability to identify twenty different cancer types through a simple blood test.

• ITUS to Ring the NASDAQ Closing Bell on July 5th

  6/29/2018

  ITUS Corporation announced that it has been invited by NASDAQ to ring the closing bell on July 5, 2018.

• ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

  6/13/2018

  ITUS Corporation announced that it has chosen prostate cancer as the first commercial focus for its Cchek™, non-invasive liquid biopsy cancer detection platform.

• ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

  3/27/2018

  Prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.

• ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

  3/12/2018

  Data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.

• ITUS Corporation Forms Alliance with Serametrix Corporation

  3/5/2018

  Serametrix flow cytometry and related data analysis services are already widely used in immunotherapy drug trials.

• ITUS Presents Positive Data From its Early Cancer Detection Technology at ASCO-SITC Symposium

  1/29/2018

  Studies over the past decade have demonstrated that there is a dynamic interaction between a patient's immune system and the existence of a tumor.

• ITUS Corporation Terminates at-the-Market Offering

  12/12/2017

  The Company had not sold any shares, and will no longer offer any shares, under this program.

• ITUS Corporation Licenses CAR-T Technology From the Wistar Institute

  11/14/2017

  ITUS has formed a subsidiary, Certainty Therapeutics, to develop and commercialize the innovative CAR-T technology.